BioMeetingpoint at the Biotechnica

The Biotechnology Thematic Group (BioTG) of the IRC Network together with other European partners are organising again the BioMeetingpoint for companies, R&D organisations and stakeholders to hold bilateral meetings at Biotechnica Hannover, Europe's leading biotechnology trade fair, which will take place in Hannover, Germany 9 - 11 October 2007.

Since 1985 Biotechnica Hannover has been the most important trade show in Europe for biotechnology. For the BioMeetingpoint a catalogue of company profiles and technology offers and requests will be available electronically and will allow participating companies and organisations to organise their individual meetings in advance.

The BioMeetingpoint functions as an "interface between research and the private sector" allowing new technologies, processes, patents and licenses to be offered and experience in financing, production, marketing and distribution to be requested, thus bringing compatible partners together.

The BioMeetingpoint is the ideal environment for:

  • Enterprises offering and/or using innovative technologies.
  • Enterprises that are looking for expertise and know-how in the areas of production, marketing and distribution or wish to provide this knowledge to others.
  • Scientists and research institutes offering application-oriented research results.
  • Start-ups.
  • Investors.

They will have the opportunity to get to know selected partners during individual discussions, which aim to pave the way for future co-operations.

For further information, please visit:
http://www.biomeetingpoint.org

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...